Dubious about prophylaxis

Fund managers unenthusiastic about prophylactic use of Gilead's Truvada in HIV

Buysiders showed little enthusiasm for data showing efficacy for Truvada emtricitabine/tenofovir as a prophylaxis for HIV. But at least one sellside analyst is throwing out blockbuster market projections.

For its part, Gilead Sciences Inc. (NASDAQ:GILD), which markets the fixed-dose combination of two nucleoside analog reverse transcriptase inhibitors, last week told the Piper Jaffray Healthcare Conference in New York that it is working with

Read the full 622 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE